| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,149,771 ) |
| | 2025 | 2025 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44TR004557 | A cross-species preclinical platform to enhance the translation of new medicines | 001 | 3 | NIH | 11/13/2024 | $1,149,771 |
| | 2025 | 2023 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44TR004557 | A cross-species preclinical platform to enhance the translation of new medicines | 000 | 1 | NIH | 10/17/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,742,384 ) |
| | 2024 | 2024 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | U44TR004795 | High-Throughput NMJ Assay for Botox Potency Screening | 000 | 2 | NIH | 12/18/2023 | $910,019 |
| | 2024 | 2024 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44TR004557 | A cross-species preclinical platform to enhance the translation of new medicines | 000 | 2 | NIH | 11/8/2023 | $832,365 |
| | 2024 | 2021 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 000 | 3 | NIH | 1/19/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $769,570 ) |
| | 2023 | 2023 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44TR004557 | A cross-species preclinical platform to enhance the translation of new medicines | 001 | 1 | NIH | 8/1/2023 | $0 |
| | 2023 | 2023 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 000 | 3 | NIH | 11/15/2022 | $169,156 |
| | 2023 | 2023 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | U44TR004795 | High-Throughput NMJ Assay for Botox Potency Screening | 000 | 1 | NIH | 8/1/2023 | $275,766 |
| | 2023 | 2023 | CURI BIO INC | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44TR004557 | A cross-species preclinical platform to enhance the translation of new medicines | 000 | 1 | NIH | 5/31/2023 | $324,648 |
|
| Issue Date FY: 2022 ( Subtotal = $1,115,232 ) |
| | 2022 | 2022 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 004 | 3 | NIH | 8/31/2022 | $242,088 |
| | 2022 | 2022 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 000 | 2 | NIH | 3/6/2022 | $123,144 |
| | 2022 | 2022 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 003 | 3 | NIH | 8/30/2022 | $750,000 |
| | 2022 | 2021 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 002 | 2 | NIH | 3/9/2022 | $38,243 |
| | 2022 | 2020 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43HL150971 | Maturation of stem cell-derived cardiomyocytes using a simulated microgravity bioreactor and combinations of extracellular developmental cues | 000 | 1 | NIH | 7/25/2022 | $0 |
| | 2022 | 2020 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43HL154928 | Cryopreserving Stem Cell-Derived Cardiomyocytes in Ready-to-use Assay Plates for Improved Reproducibility of Drug Toxicity Testing | 000 | 1 | NIH | 7/12/2022 | $0 |
| | 2022 | 2020 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 001 | 1 | NIH | 3/9/2022 | -$38,243 |
| | 2022 | 2019 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43EB028183 | Low-cost, Roll-to-Roll Manufacturing of Nanoscale Biomimetic Scaffolds for Enhanced Biological Cell Culture | 000 | 1 | NIH | 12/20/2021 | $0 |
| | 2022 | 2019 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43EB029311 | Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs | 000 | 1 | NIH | 12/20/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,743,756 ) |
| | 2021 | 2021 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 001 | 2 | NIH | 3/19/2021 | $69,068 |
| | 2021 | 2021 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 003 | 3 | NIH | 7/28/2021 | $179,200 |
| | 2021 | 2021 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 000 | 2 | NIH | 9/2/2021 | $750,000 |
| | 2021 | 2021 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 002 | 3 | NIH | 7/27/2021 | $745,488 |
| | 2021 | 2019 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 000 | 1 | NIH | 2/23/2021 | $0 |
| | 2021 | 2019 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43HL146043 | A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells | 000 | 1 | NIH | 10/19/2020 | $0 |
| | 2021 | 2019 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 000 | 3 | NIH | 2/9/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,479,262 ) |
| | 2020 | 2020 | CURI BIO, INC. | 3000 WESTERN AVE | SEATTLE | WA | 98121-1023 | KING | USA | R43HL154928 | Cryopreserving Stem Cell-Derived Cardiomyocytes in Ready-to-use Assay Plates for Improved Reproducibility of Drug Toxicity Testing | 000 | 1 | NIH | 9/11/2020 | $252,131 |
| | 2020 | 2020 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL151094 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs | 000 | 1 | NIH | 7/27/2020 | $225,000 |
| | 2020 | 2020 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 000 | 2 | NIH | 6/5/2020 | $750,000 |
| | 2020 | 2020 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43HL150971 | Maturation of stem cell-derived cardiomyocytes using a simulated microgravity bioreactor and combinations of extracellular developmental cues | 000 | 1 | NIH | 7/15/2020 | $252,131 |
| | 2020 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43HL146043 | A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells | 000 | 1 | NIH | 3/20/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,053,680 ) |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 003 | 3 | NIH | 7/24/2019 | $129,050 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 002 | 3 | NIH | 7/22/2019 | $123,510 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 001 | 3 | NIH | 7/11/2019 | $747,868 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43EB028183 | Low-cost, Roll-to-Roll Manufacturing of Nanoscale Biomimetic Scaffolds for Enhanced Biological Cell Culture | 000 | 1 | NIH | 9/13/2019 | $221,713 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43EB029311 | Multiplexed quantitative measurements of field potential and contractility on biomimetically-matured hPSC-CMs | 000 | 1 | NIH | 9/14/2019 | $225,000 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL149566 | Bioengineering Mature Human Pluripotent Stem Cell-Derived Cardiomyocytes for Predictive Drug-Induced Toxicity Testing | 000 | 1 | NIH | 8/16/2019 | $225,000 |
| | 2019 | 2019 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43HL146043 | A Combinatorial Bioreactor for Electromechanical Conditioning of Differentiated Stem Cells | 000 | 1 | NIH | 5/17/2019 | $225,000 |
| | 2019 | 2018 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 000 | 2 | NIH | 12/14/2018 | $156,539 |
| | 2019 | 2017 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43CA221659 | A Nanopatterned Interdigitated Electrode Array Device for Anti-migratory Cancer Drug Screening | 000 | 1 | NIH | 12/4/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $591,896 ) |
| | 2018 | 2018 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R44HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 000 | 2 | NIH | 9/21/2018 | $591,896 |
| | 2018 | 2016 | NANOSURFACE BIOMEDICAL, INC. | 4000 MASON RD STE 304 | SEATTLE | WA | 98195-0001 | KING | USA | R43HL131169 | High-throughput nanoMEA-based Proarrhythmia Assay | 000 | 1 | NIH | 2/5/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $225,000 ) (Continued on the next page) |
|
